Loxo Oncology Appoints Chief Medical Officer, New Director

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Loxo Oncology Appoints Chief Medical Officer, New Director

STAMFORD, Conn., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO ) ("Loxo"), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, today announced the promotion of Jennifer Low, M.D., Ph.D. to Chief Medical Officer (CMO) and the appointment of Lori Kunkel, M.D. as a non-employee member of the Loxo Board of Directors.

In addition to being named CMO, Dr. Low continues to serve as the company's Executive Vice President, Research and Development. In conjunction with Dr. Low's promotion, Dr. Lori Kunkel, who has served as Acting CMO since July 2013, will join the Loxo Board of Directors as a non-employee director, replacing Dr. Dov Goldstein.

"Jennifer joined Loxo this year as part of our executive team expansion, and her impact could be felt on day one—she is an outstanding leader with deep expertise in targeted therapeutics and oncology research, garnered through her successful drug development career," said Josh Bilenker, MD, Chief Executive Officer. "Lori's instrumental role in the design and initiation of the LOXO-101 clinical trial, her proven drug development expertise and her valuable industry perspective make her a welcome addition to our Board. As we continue to grow our organization and advance our clinical program, we're delighted to continue working with both Jennifer and Lori in their new roles."

Prior to joining Loxo, Dr. Low served as Senior Group Medical Director in Product Development at Genentech, a member of the Roche Group. In that role, Dr. Low led the development of Erivedge (vismodegib, the first approved hedgehog pathway inhibitor) from the first-in-man study to global approvals, and supervised the development teams for numerous drugs and drug candidates including Zelboraf (vemurafenib, the first approved inhibitor of BRAF V600), Tarceva (erlotinib, EGFR inhibitor) and cobimetinib (GDC-0973, MEK1/2 inhibitor). Prior to Genentech, Dr. Low was a Senior Investigator in the Investigational Drug Branch of the Cancer Therapy Evaluation Program at the National Cancer Institute (NCI) and an attending physician at the National Institutes of Health Clinical Center in Bethesda, Maryland. Dr. Low trained in internal medicine at University of California Davis, and in medical oncology at the NCI, earning board certifications in these specialties. She received her M.D. and Ph.D. degrees from Georgetown University, and her undergraduate degree from the California Institute of Technology.

Prior to Loxo, Dr. Kunkel served as CMO at Pharmacyclics from November 2011 until August 2013 where she was responsible for building and leading an integrated clinical development and medical affairs organization highlighted by the approval of IMBRUVICA. Previously she served as CMO at Proteolix, acquired by Onyx, where she oversaw the clinical development of KYPROLIS. She has held senior roles at ACT Therapeutics, Syndax, Xencor, and Genitope. Dr. Kunkel trained in internal medicine at Baylor College of Medicine, and in hematology-oncology at University of Southern California (USC) and University of California Los Angeles earning board certification in these specialties. Dr. Kunkel received her M.D. from USC and her B.A. degree from University of California San Diego.

In addition to the new appointments, Loxo also announced that Dr. Mikel Moyer, Chief Scientific Officer for Loxo, has resigned from his position at the company.

About Loxo Oncology

Loxo Oncology develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo's development approach translates key scientific insights relating to the oncogenic drivers of cancer into drugs that are potent and highly selective for their intended targets. This approach is intended to allow for the development of drugs with a high probability of clinical success while reducing the time, costs and risks of drug development. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery. For more information, visit www.loxooncology.com .

Company: Jacob S. Van Naarden Vice President, Corporate Development and Strategy Investors: Peter Rahmer The Trout Group, LLC 646-378-2973 Media: Karen Sharma MacDougall Biomedical Communications 781-235-3060

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 216

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 157

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 274

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Airtel Money Upgrade Raises the Stakes in East Africa

Updated Category News Views 32

Mobile money lives or dies in the irritating little moments: a transfer that hangs, a menu that makes people punch five buttons too many, a merchant payment that simply will not clear. Airtel Money is attacking that friction in Malawi and Tanzania with an enhanced platform from Comviva, and this is more consequential than the usual software-refresh chest thumping. In...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 220

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Frontline Claims Survey Tests AI's Real Desk Impact

Updated Category News Views 36

Claims software can look brilliant in a conference-room demo and still create a fresh pile of headaches for the person handling a real injured worker’s file. That is why the 2026 Workers’ Compensation Benchmarking Study opening its survey to frontline claims professionals matters more than the usual industry questionnaire. This is an operating-reality check, not just...

Continue Reading
Tim Hortons Bets on ELF Cheer for U.S. Holiday Visits

Updated Category News Views 0

Nothing says holiday restaurant marketing quite like putting spaghetti-shaped whipped topping on hot chocolate and trusting a 2003 movie to do the selling. Tim Hortons is rolling out an ELF-inspired menu at participating U.S. locations starting November 18, 2026, pairing the chain with Warner Bros. Consumer Products and mining Buddy the Elf's sugar-fueled world for a...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 64

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

Lexicon Pharmaceuticals Unveils Q3 Financials and Future Plans

Updated Category News Views 138

Third Quarter Financial Highlights of Lexicon Pharmaceuticals Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has disclosed its financial performance for the third quarter of 2025, highlighting significant revenue increases attributed primarily to strategic licensing agreements and product sales. Strategic Partnerships and Revenue Growth In an impressive leap, Lexicon's...

Continue Reading
Growing Innovations in Robotic Dentistry to 2034 and Beyond

Updated Category News Views 178

The Rise of Robotic Dentistry and Its Market Growth The shift towards technological integration in the healthcare sector has begun a revolutionary transformation in dental care. The robotic dentistry market is anticipated to grow significantly, projected to increase from USD 617.39 million in 2024 to an approximate USD 2.24 billion by 2034. This acceleration is based on a...

Continue Reading
Chipotle Lawsuit Update: Key Actions for Shareholders

Updated Category News Views 126

Important Information for Chipotle Shareholders Shareholders of Chipotle Mexican Grill, Inc. (NYSE: CMG) are being advised about an ongoing class action lawsuit that could impact their investments. It is vital for all affected shareholders to take note of critical deadlines and actions they need to undertake to ensure their rights and potential recoveries are protected....

Continue Reading
Quisitive Technology Solutions Reports Q2 2024 Financial Results

Updated Category News Views 144

Quisitive Reports Second Quarter 2024 Financial Results Quisitive Technology Solutions Inc. (“Quisitive” or the “Company”) (TSXV: QUIS, OTCQX: QUISF), a leading provider of Microsoft Cloud and AI solutions, has announced its financial results for the second quarter ending June 30, 2024. Management Commentary Quisitive's CEO, Mike Reinhart, commented, “The first...

Continue Reading
Natural Grocers Reports Strong Fiscal 2024 Performance

Updated Category News Views 231

Natural Grocers by Vitamin Cottage Sees Remarkable Growth in Fiscal 2024 Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) has unveiled its financial results for the fourth quarter and full year of fiscal 2024. The report highlights significant sales and earnings achievements, showcasing the company’s robust performance in a competitive grocery market. Exceptional...

Continue Reading